Liquidia Corporation Expands Partnership with Pharmosa Biopharm to Advance Inhaled Treprostinil Therapy

Liquidia Corporation LQDA, a biopharmaceutical firm specializing in the development and commercialization of novel treatments, recently announced the extension and modification of its exclusive licensing agreement with partner Pharmosa Biopharm. The amended collaboration focuses on the advancement of the sustained release inhaled product, Treprostinil, referred to as L606. The partnership aligns with Liquidia's strategic initiatives to address significant unmet medical needs within the United States.

Enhanced Collaboration Aims to Accelerate L606 Development

This renewed collaboration is expected to accelerate the process of bringing L606 to market. L606 utilizes a proprietary PRINT technology, designed to enable a sustained release of medication directly to the lungs. By optimizing the delivery mechanism, the companies aim to improve the quality of life for patients requiring treprostinil therapy. By amending the existing agreement, Liquidia and Pharmosa underscore their commitment to innovation and patient care in the pulmonary hypertension community.

Liquidia's Market Presence and Ongoing Endeavors

Liquidia Corporation, headquartered in Morrisville, North Carolina, is committed to meeting the unmet needs of patients through the development, manufacturing, and marketing of innovative pharmaceutical products. The expanded partnership with Pharmosa Biopharm exemplifies Liquidia's continuous effort to provide effective treatment options and to solidify its presence in the healthcare market. With this strategic move, LQDA signals its potential for growth and its dedication to advancing therapeutic solutions for chronic conditions.

Liquidia, Pharmosa, Treprostinil